Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

3.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
3.0K
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

1.7K
The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
1.7K
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

2.8K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
2.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

100
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
100
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.6K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

[Medical care situation of people with vitiligo : A pilot and feasibility study on guideline-oriented management in German dermatology practices].

Dermatologie (Heidelberg, Germany)·2026
Same author

Epidemiology and Comorbidity of Vitiligo in Germany: A Claims Data Analysis.

Acta dermato-venereologica·2026
Same author

Definition of Severity and Relapse for Vitiligo: An International Consensus Statement.

JAMA dermatology·2026
Same author

Validation of Self-Reported Vitiligo Prevalence among Adults in the USA and Europe Using the 2024 National Health and Wellness Survey.

Dermatology and therapy·2026
Same author

The α-MSH-MC1R Axis Modulates Sex-Specific Senescence and Inflammation Processes in Human Articular Chondrocytes and Mice Knee Joints.

Aging and disease·2026
Same author

Multilingual Digital Search Behavior Reveals Cultural Disparities in Vitiligo Information Needs in Germany.

International journal of dermatology·2026

Related Experiment Video

Updated: May 29, 2025

Direct Reprogramming of Mouse Fibroblasts into Melanocytes
09:38

Direct Reprogramming of Mouse Fibroblasts into Melanocytes

Published on: August 27, 2021

2.0K

[Vitiligo-update on pathogenesis, diagnostics and therapy].

Paloma Seidel1, Markus Böhm2

  • 1Klinik für Hautkrankheiten, Universitätsklinikum Münster, Von-Esmarch-Str. 58, 48149, Münster, Deutschland.

Dermatologie (Heidelberg, Germany)
|February 4, 2025
PubMed
Summary

Vitiligo, a skin depigmentation disease, involves melanocyte destruction and is linked to autoimmune responses. A new topical Janus kinase inhibitor offers a specific therapy for nonsegmental vitiligo.

Keywords:
Calcineurin inhibitorsComorbidityJanus kinase inhibitorPhototherapyTopical corticosteroids

More Related Videos

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
06:41

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

8.9K
Quantification of Hypopigmentation Activity In Vitro
06:08

Quantification of Hypopigmentation Activity In Vitro

Published on: March 6, 2019

11.2K

Related Experiment Videos

Last Updated: May 29, 2025

Direct Reprogramming of Mouse Fibroblasts into Melanocytes
09:38

Direct Reprogramming of Mouse Fibroblasts into Melanocytes

Published on: August 27, 2021

2.0K
A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
06:41

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

8.9K
Quantification of Hypopigmentation Activity In Vitro
06:08

Quantification of Hypopigmentation Activity In Vitro

Published on: March 6, 2019

11.2K

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Vitiligo is a common skin condition causing depigmentation due to melanocyte destruction.
  • Nonsegmental vitiligo (NSV) is a chronic autoimmune disease involving T-cell activation and immune memory.
  • Current vitiligo treatments are limited, highlighting the need for improved patient care and novel therapies.

Purpose of the Study:

  • To review the current understanding of vitiligo pathogenesis, focusing on the role of the interferon signature.
  • To discuss the recent advancements in vitiligo treatment, including the approval of new specific therapies.
  • To highlight the significance of new therapeutic options for patients with nonsegmental vitiligo.

Main Methods:

  • Literature review of vitiligo pathogenesis and treatment options.
  • Analysis of recent clinical trial data for novel vitiligo therapies.
  • Focus on the role of interferon pathways and Janus kinase inhibitors in vitiligo.

Main Results:

  • The interferon signature plays a key role in the pathobiology of vitiligo.
  • Topical Janus kinase (JAK) inhibitors, such as ruxolitinib, represent a new class of vitiligo-specific therapies.
  • Ruxolitinib has been approved for the treatment of nonsegmental vitiligo (NSV).

Conclusions:

  • New insights into vitiligo pathogenesis have led to the development of targeted therapies.
  • The approval of topical JAK inhibitors marks a significant advancement in managing NSV.
  • Improved therapeutic options are crucial for enhancing the quality of life for vitiligo patients.